Combinations of RMC-9805 with either RMC-6236 (RASMULTI(ON) inhibitor) or an anti-EGFR antibody improved the depth of the response and delayed the onset of resistance in KRAS G12D CRC models [84]. Here, KRAS is linked to colorectal carcinoma.